Ignite Creation Date:
2025-12-24 @ 12:46 PM
Ignite Modification Date:
2026-01-01 @ 1:14 PM
Study NCT ID:
NCT02614261
Status:
COMPLETED
Last Update Posted:
2022-05-18
First Post:
2015-11-23
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-11-30
Start Date Type:
ACTUAL
Primary Completion Date:
2017-03-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-07-14
Completion Date Type:
ACTUAL
First Submit Date:
2015-11-23
First Submit QC Date:
None
Study First Post Date:
2015-11-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-10-19
Results First Submit QC Date:
None
Results First Post Date:
2019-01-07
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2018-03-19
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2022-04-25
Last Update Post Date:
2022-05-18
Last Update Post Date Type:
ACTUAL